Posted in | News | Medical Sensor

Telcare’s Cellular-Enabled Blood Glucose Monitor Receives 2012 Gold Edison Award

Telcare has announced that its wireless-enabled blood glucose monitoring system has won the 2012 Gold Edison Award. The FDA-cleared device was introduced by Telcare in February 2012 and has been designed to transmit important information wirelessly to diabetic patients, caregivers and doctors.

(From left) Matthew Tendler (VP, Telcare), Dr. Jonathan Javitt (CEO, Telcare), Thomas Stat (Chairman, Edison Awards Steering Committee) Image by: Wendy Moger-Bross

Telcare’s wireless glucose meter utilizes cellular communication to transmit the reading of the blood glucose level to a secure database, which can be accessed by the doctor, family member and caregiver. Furthermore, it also tracks the results and identifies potential problems.

The CEO of Telcare, Dr. Jonathan Javitt stated that receiving the Edison award for innovation is a great honour. Dr Javitt also added that the capabilities offered by the wireless glucose meter can potentially transform the lives of millions of diabetic patients in America.

Featuring Diabetes Pal, the blood glucose monitoring system offered by Telcare is the highest rated smartphone app available for diabetes. Diabetes Pal enables the patient’s family to view the results in real-time and also offers the patient support through social networking.

The Chairman of Edison Awards Steering Committee, Thomas Stat explained that the device was recognized for the award for its potential at steering diabetic patients towards a healthier lifestyle.

Diabetes Pal is being distributed by Telcare through the iTunes store at no charge, enabling patient’s o use the app independent of the Telcare system.

Source: http://www.telcare.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Choi, Andy. (2019, February 24). Telcare’s Cellular-Enabled Blood Glucose Monitor Receives 2012 Gold Edison Award. AZoSensors. Retrieved on February 28, 2024 from https://www.azosensors.com/news.aspx?newsID=4144.

  • MLA

    Choi, Andy. "Telcare’s Cellular-Enabled Blood Glucose Monitor Receives 2012 Gold Edison Award". AZoSensors. 28 February 2024. <https://www.azosensors.com/news.aspx?newsID=4144>.

  • Chicago

    Choi, Andy. "Telcare’s Cellular-Enabled Blood Glucose Monitor Receives 2012 Gold Edison Award". AZoSensors. https://www.azosensors.com/news.aspx?newsID=4144. (accessed February 28, 2024).

  • Harvard

    Choi, Andy. 2019. Telcare’s Cellular-Enabled Blood Glucose Monitor Receives 2012 Gold Edison Award. AZoSensors, viewed 28 February 2024, https://www.azosensors.com/news.aspx?newsID=4144.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.